Sinclair Plans to Enter XPrize with Oral Rejuvenation Drug
Dr. David Sinclair of Harvard University is planning a human trial of an oral "reprogramming" drug, SL-100, within the framework of the XPrize competition. The attempt at whole-body rejuvenation sparks both hope and caution.
Reporting by MIT Technology Review has revealed that Dr. David Sinclair, a leading figure in longevity science at Harvard Medical School, is planning a human trial of an oral drug aimed at whole-body rejuvenation. The trial will be conducted as part of a competition organized by the XPrize Foundation with a total prize pool of $101 million.
Dr. Sinclair has long predicted that “one day, you’ll be able to go to the doctor and get a prescription to become 10 years younger.” This new plan represents a bold attempt to turn that vision into reality.
Overview of the XPrize Competition
The XPrize Foundation will award prizes to teams that rejuvenate “apparent age” as measured by improvements in immune function, cognitive function, and muscle function. The grand prize will go to the team that demonstrates a relative improvement of more than 10 years after one year of treatment.
In a phone interview, Dr. Sinclair confirmed the plan to administer a mixture of oral drugs to volunteers and seek “evidence of age reversal in humans.” If realized, this trial would represent a significant advance in aging research using so-called epigenetic reprogramming.
How Chemical Reprogramming Works
Epigenetic reprogramming is a technology based on a powerful set of genes discovered 20 years ago. These genes can revert adult cells to a state resembling embryonic stem cells. The age-reversal effect is believed to occur through the resetting of molecular controls called epigenetic marks on DNA. These marks determine the overall metabolism and identity of cells.
Currently, companies are racing to apply this phenomenon to new rejuvenation therapies. In January, a company called Life Biosciences, with which Dr. Sinclair is involved, received approval for the first human trial using powerful reprogramming genes. The company announced today that it has treated its first patient. However, that trial involves complex gene therapy and is confined to the eyes of patients, aimed at treating diseases such as glaucoma.
In contrast, Dr. Sinclair’s new plan is more ambitious: the development of an oral reprogramming drug that can be swallowed to promote effects throughout the body. “What we are aiming for is to epigenetically repair animals, and eventually humans,” he said. The alternative approach, chemical reprogramming, uses drugs to mimic the effects of embryonic genes. Importantly, drug compounds can reach most or all cells in the body through the bloodstream.
Expert Opinions: Potential and Challenges
However, some experts are cautious. They point out that, at least in the lab, the chemical process is very harsh and not particularly efficient. Sergey Belichko, founder of the stealth reprogramming company Soxogen in Boston, said, “Everyone dreams of whole-body rejuvenation. I think it’s a great goal.” But he warned, “These chemicals are used at very high concentrations for cell reprogramming.”
Dr. Sinclair declined to disclose the exact composition of the investigational drug, codenamed “SL-100,” calling it “extremely secret.” However, he has previously published lab research on what he calls an “epigenetic age reversal cocktail,” which involves a mixture of potent chemicals.
Editorial Opinion
In the short term, if Dr. Sinclair’s plan comes to fruition, it will likely accelerate attention and investment in the field of epigenetic reprogramming. In particular, the competitive framework of XPrize could lead to faster progress than traditional pharmaceutical company-led trials. However, verifying the safety and efficacy of chemical reprogramming will take years, and dealing with unexpected side effects from systemic administration (such as cancer risk) appears to be the biggest hurdle.
From a long-term perspective, the successful development of an oral rejuvenation drug could fundamentally transform the medical paradigm. If it not only extends lifespan but dramatically extends healthspan, it would affect society as a whole, from healthcare costs and social security systems to individual career planning. However, given past instances of exaggerated claims and reproducibility issues in aging research, a healthy skepticism toward this plan is warranted.
The editorial board focuses on the issue often highlighted in longevity science: the “gap between evidence and hype.” Dr. Sinclair is known for actively publicizing his research results, but critics have pointed out selective interpretation of data and excessive orientation toward commercialization. Whether the SL-100 trial will be conducted in a way that allows verification by independent third parties, and whether the results will truly lead to future longevity medicine, are likely the biggest concerns for readers.
References
Frequently Asked Questions
- What is epigenetic reprogramming technology?
- It is a technology that resets epigenetic marks that control gene expression patterns without altering the DNA sequence of cells. It originates from the iPS cell creation technology discovered by Professor Shinya Yamanaka in 2006, and current research focuses on its application to "rejuvenation" by returning the epigenetic state, which changes with aging, to a younger state. There are two methods: chemical reprogramming using only chemical substances, and a method using gene introduction.
- What outcomes are required in the rejuvenation category of the XPrize competition?
- The goal is to rejuvenate "apparent age" as measured by improvements in immune function, cognitive function, and muscle function. The grand prize is expected to be awarded to a team that demonstrates a relative improvement of more than 10 years after one year of treatment. A total prize pool of $101 million has been set.
- What concerns exist about Dr. Sinclair's oral drug SL-100?
- The compounds used in chemical reprogramming must be used at very high concentrations, and the safety of systemic administration is the biggest concern. Additionally, there are concerns about the risk of cells becoming cancerous if reprogramming is incomplete, as well as the challenge of ensuring that effects are evenly distributed to all organs in the body. Dr. Sinclair has not disclosed the exact composition, raising questions about transparency.
Comments